Skip to main content
. Author manuscript; available in PMC: 2009 Sep 3.
Published in final edited form as: Mol Ther. 2008 Apr 1;16(6):1056–1064. doi: 10.1038/mt.2008.60

Figure 7. AAV-IGF-1 treatment reduced disease-induced elevations in nitric oxide synthase (NOS) activity and peroxynitrite formation in amyotrophic lateral sclerosis (ALS) mice.

Figure 7

(a) NOS and (b) 3-nitrotyrosine staining (peroxynitrite marker) in the spinal cord of 110-day-old superoxide dismutase-1 mice treated with either AAV-GFP or AAV-IGF-1 at 90 days of age. (c) MetaMorph analysis of NOS and 3-nitrotyrosinestained spinal cord sections taken from ALS mice treated with either AAV-IGF-1 or AAV-GFP (P < 0.05) and wild-type (WT) controls. AAV, adeno-associated virus; GFP, green fluorescent protein; IGF, insulin-like growth factor.